Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
CONy 2023
ACTRIMS 2023
ISC 2023
EHC 2022
AES 2022
WSC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Messoud Ashina
2:43
The burden of migraine: from individuals to society
Messoud Ashina
• 23 Jun 2022
1:47
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial
Messoud Ashina
• 23 Jun 2022
3:04
PACAP as a future target for anti-migraine medication
Messoud Ashina
• 23 Jun 2022
3:19
Real-world studies show effectiveness of anti-CGRP mAbs in difficult to treat patients with migraine
Messoud Ashina
• 23 Jun 2022
2:24
Latest guidelines on anti-CGRP antibodies: first-line and long-term use
Messoud Ashina
• 23 Jun 2022
4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina
• 29 May 2020
2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina
• 29 May 2020
3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina
• 29 May 2020
3:16
PEARL study: fremanezumab for chronic or episodic migraine in the real world
Messoud Ashina
• 29 May 2020